112366-39-9

Usage

Imidazole ring

A 5-membered aromatic ring with two nitrogen atoms at positions 1 and 3, contributing to its stability and potential biological activity.

Carboxylic acid group

A functional group (-COOH) that provides acidity and can form hydrogen bonds, which may influence solubility and reactivity.

Methyl ester

A functional group (-COOCH3) derived from the esterification of the carboxylic acid group, which can affect the compound's reactivity and volatility.

3-[1-(3,4-dichlorophenyl)propyl] side chain

A structural feature that extends from the imidazole ring, containing a 3,4-dichlorophenyl group and a propyl chain, which may contribute to the compound's biological activity and selectivity.

Thioxo group

A sulfur-oxygen double bond (-S(=O)-) that is isoelectronic with an oxo group (-C(=O)-), potentially influencing the compound's reactivity and stability.

Potential pharmaceutical applications

The presence of various functional groups and the dichlorophenyl group suggests that 1H-Imidazole-4-carboxylic acid, 3-[1-(3,4-dichlorophenyl)propyl]-2,3-dihydro-2-thioxo-, methyl ester may have biological activity, making it a potential candidate for drug development or as an intermediate in the synthesis of biologically active compounds.

Use as a research starting material

Due to its unique structure and functional groups, 1H-Imidazole-4-carboxylic acid, 3-[1-(3,4-dichlorophenyl)propyl]-2,3-dihydro-2-thioxo-, methyl ester may be used as a starting material for the synthesis of other important compounds in chemical research.

Need for further analysis and experimentation

The specific properties, reactivity, and uses of 1H-Imidazole-4-carboxylic acid, 3-[1-(3,4-dichlorophenyl)propyl]-2,3-dihydro-2-thioxo-, methyl ester are not fully known and require additional investigation to determine its potential applications and limitations.

Upstream product

• 107-31-3 Methyl formate 
• 333-20-0 potassium thioacyanate 
• 847448-00-4 {[1-(3,4-dichloro-phenyl)-propyl]-formyl-amino}-acetic acid methyl ester 
• 847448-34-4 [1-(3,4-dichloro-phenyl)-propylamino]-acetic acid methyl ester 

Downstream Products

• 871343-71-4 C₁₅H₁₄Cl₂N₄OS 
• 742107-78-4 C₁₃H₁₂Cl₂N₂O₂S 
• 742107-77-3 C₁₃H₁₄Cl₂N₂OS 
• 742107-81-9 C₁₄H₁₄Cl₂N₂O₂S 
• 742107-82-0 C₁₄H₁₄Cl₂N₂O₂S 
• 871343-40-7 C₂₂H₂₂Cl₂N₂O₃S 
• 871343-28-1 3-[1-(3,4-dichloro-phenyl)-propyl]-2-mercapto-3H-imidazole-4-carbonyl chloride 
• 742107-78-4 3-[1-(3,4-dichloro-phenyl)-propyl]-2-mercapto-3H-imidazole-4-carboxylic acid 

Relevant academic research and scientific papers

2-Mercaptoimidazoles, a new class of potent CCR2 antagonists

We describe the synthesis and SAR of a new class of CCR2 antagonists based on a 2-mercaptoimidazole scaffold. The initial lead 1a was optimized to the 3,4-disubstituted analogues 1p-(S) and 1q-(S), which have IC50 values in the MCP-1 induced Ca

MERCAPTOIMIDAZOLES AS CCR2 RECEPTOR ANTAGONISTS

The present invention relates to a compound of formula (I), a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine or a stereochemically isomeric form thereof, wherein R1 represents hydrogen, C1-66alkyl, C3-7cycloalkyl, C1-66alkylo xyC1 -6alkyl, di(C1-6alkyl)aminoC1-6alkyl, aryl or heteroaryl; each R2 independently represents halo, C1-6alkyl, C1-6alkyloxy, C1-6alkylthio, polyhaloC1-6alkyl, polyhaloC1-6alkyloxy, cyano, aminocarbonyl, amino, mono-or di(C1-4alkyl)amino, nitro, aryl or aryloxy; R3 represents hydrogen, cyano, optionally subst ituted C1-66alkyl, C(=O)-O-R5, C(=O)-NR6aR6b, C(=S)-NR6aR6b, S(=O)2-NR6aR6b or C(=O)-R7; R4 represents hydrogen or C1-6alkyl; n is 1, 2, 3, 4 or 5; Z represents a cyclic ring system. The invention also relates to processes for preparing the compounds of formula (I), their use as CCR2 antagonists and pharmaceutical compositions comprising them.

MERCAPTOIMIDAZOLES AS CCR2 RECEPTOR ANTAGONISTS

The present invention relates to a compound of formula (I),a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine and a stereochemically isomeric form thereof, wherein R1 is hydrogen, C1-6alkyl, C3-7cycloalkyl, aryl or heteroaryl; R2 is halo, C1-6alkyl, C1-6alkyloxy, C1-6alkylthio, polyhaloC1-6alkyl, polyhaloC1-6alkyloxy, cyano, aminocarbonyl, amino, mono-or di(C1-4alkyl)amino, nitro, aryl or aryloxy; R3 is hydrogen, cyano, C1-6alkyl optionally substituted with hydroxy, C(=O)-O-R5, C(=O)-NR6aR6b, S(=O)2-NR6aR6b, C(=O)-R7; R4 is hydrogen, cyano, C1-6alkyl optionally substituted with hydroxy, C(=O)-O-R5, C(=O)-NR6aR6b, S(=O)2-NR6aR6b, C(=O)-R7; n is 1, 2, 3, 4 or 5;provided that at least one of R3 or R4 is other than hydrogen; and that if R3 represents C(=O)-OH, C(=O)-O-C1-6alkyl or C(=O)-O-C2-6alkenyl, then R4 is other than hydrogen; and that if R3 represents CH2OH and R1 represents hydrogen, then R4 is other than hydrogen; and that if R3 represents C(=O)-NH-C1-4alkyl-NH2 and R1 represents hydrogen, then R4 is other than hydrogen; and that if R3 represents formula (II) and R1 represents hydrogen, then R4 is other than hydrogen; having CCR2 receptor antagonistic properties. The invention also relates to processes for preparing the compounds of formula (I) and pharmaceutical compositions comprising them.